Erin McCleary, OD
Optometrist · Plainville, CTNPI 1477743953
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,366 of the $12,588 with a category attached, or 74.4%. 23 manufacturers reported payments, led by Coopervision Inc. at 24.7% of the total. 2025 is the largest year on record at $4,148, 4.0 times the $1,025 reported in 2019. Among optometrist clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $55.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$3K
- Alcon$3K
- Bausch & Lomb Americas Inc.$2K
- AbbVie$991
- Sun Pharmaceutical Industries Inc.$810
- Tarsus Pharmaceuticals, Inc.$581
- plus $3K from 17 others
What the payments were for
- Travel & lodging$3,22226%
- Food & beverage$9,36674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 26 | $3,110 |
| Alcon | 28 | $2,930 |
| Bausch & Lomb Americas Inc. | 39 | $1,510 |
| AbbVie(2 entities) | 17 | $991 |
| Sun Pharmaceutical Industries Inc. | 24 | $810 |
| Tarsus Pharmaceuticals, Inc. | 17 | $581 |
| Harrow Eye, LLC | 20 | $453 |
| Novartis | 10 | $425 |
| Johnson & Johnson Vision Care, Inc. | 11 | $376 |
| Glaukos Corporation | 2 | $263 |
| Oyster Point Pharma, Inc. | 6 | $193 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $172 |
| Dompe US, Inc. | 7 | $144 |
| Aerie Pharmaceuticals, Inc. | 1 | $124 |
| Sight Sciences, Inc. | 2 | $124 |
| Biotissue Holdings Inc. | 5 | $107 |
| Rxsight Inc | 1 | $79 |
| Visioneering Technologies, Inc. | 2 | $65 |
| ABB Con-cise Optical Group LLC | 2 | $46 |
| Optos, Inc. | 1 | $29 |
| Shire North American Group Inc | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biofinity Contact Lens$1,909
- AIR OPTIX$1,856
- Dailies Aqua Comfort Plus$1,358
- DAILIES TOTAL1 Multifocal$443
- CEQUA$375
- INFUSE$372
- Rocklatan$272
- Rhopressa$272
- VUITY$248
- XDEMVY$238
- XIIDRA$233
- DAILIES$224
- VEVYE$222
- Precision 1$149
- SIMBRINZA$148
- iDose$140
- Acuvue$132
- MyDay Contact Lens$125
- MIEBO$125
- LUMIGAN$125
How this compares
$12,588 in reported general payments places this provider in the 95th percentile of 574 optometrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $80,542 |
| XiidraLifitegrast | 39 | $76,522 |
| VyzultaLatanoprostene Bunod | 18 | $13,173 |
| LumiganBimatoprost | 16 | $11,094 |
| VevyeCyclosporine | 12 | $9,137 |
| Cyclosporine | 13 | $8,644 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $323 |
| Timolol Maleate | 14 | $126 |
| Latanoprost | 16 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $991 | $91,63769 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,510 | $89,69457 claims |
| Harrow Eye, LLCVevye | $453 | $9,13712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 574 optometrist providers in Connecticut.
Other optometrist in Plainville
- Donald HigginsPlainville$18K
- Gary MaglioPlainville$4K
- Joseph ThimonsFairfield$340K
- Inna LazarOld Greenwich$147K
- Jennifer StewartNew Canaan$91K
- Maria PribisStamford$78K
- Michael CooperWest Hartford$44K
- Joseph PavanoNew Britain$22K
- Susan JanikWest Hartford$20K
- Richard NowakEast Windsor$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.